E-DRUG: Regulating COVID-19 Medical Products: An Urgent Need
---------------------------------------------------------------
[As emphasised in the previous E-drug message - from Lorena di Giano - genuinely affordable access must be guaranteed for low and middle income countries. BS]
Dear Fellow E-Drug Followers,
COVID-19 has triggered an urgent need for several new medical products,
including vaccines, medicines, diagnostics, personal protective equipment
(PPE), and oxygen delivery devices. As these products get developed and
begin to reach the low and middle-income countries, national regulatory
authorities will need to play an essential public health role in ensuring
that these products are safe, effective, quality-assured and affordable,
and accessible to those in need in a timely manner.
What regulatory functions are needed for COVID-19 medical products?
Check out a new infographic developed by regulatory systems experts from
USAID Medicines, Technologies, and Pharmaceutical Services (MTaPS)
Program:
https://mtapsprogram.org/blog/regulating-covid-19-medical-products-urgent-need
Javier Guzman
On behalf of USAID MTaPS Global Technical Team
www.mtapsprogram.org
The USAID MTaPS Program enables low- and middle-income countries to
strengthen their pharmaceutical systems, which is pivotal to
higher-performing health systems. The program is implemented by a
consortium of global and local partners and led by Management Sciences for
Health (MSH), a global health nonprofit.
Javier Guzman
Technical Director, Medicines, Technologies, and Pharmaceutical Services
(MTaPS) Program
Management Sciences for Health
jguzman@mtapsprogram.org